1. Home
  2. THAR vs TOVX Comparison

THAR vs TOVX Comparison

Compare THAR & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THAR
  • TOVX
  • Stock Information
  • Founded
  • THAR 2017
  • TOVX 2001
  • Country
  • THAR United States
  • TOVX United States
  • Employees
  • THAR N/A
  • TOVX N/A
  • Industry
  • THAR Biotechnology: Pharmaceutical Preparations
  • TOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • THAR Health Care
  • TOVX Health Care
  • Exchange
  • THAR Nasdaq
  • TOVX Nasdaq
  • Market Cap
  • THAR 5.5M
  • TOVX 4.5M
  • IPO Year
  • THAR 2022
  • TOVX 2006
  • Fundamental
  • Price
  • THAR $3.68
  • TOVX $0.40
  • Analyst Decision
  • THAR Strong Buy
  • TOVX Hold
  • Analyst Count
  • THAR 1
  • TOVX 1
  • Target Price
  • THAR $17.00
  • TOVX N/A
  • AVG Volume (30 Days)
  • THAR 29.2M
  • TOVX 1.1M
  • Earning Date
  • THAR 11-06-2025
  • TOVX 08-11-2025
  • Dividend Yield
  • THAR N/A
  • TOVX N/A
  • EPS Growth
  • THAR N/A
  • TOVX N/A
  • EPS
  • THAR N/A
  • TOVX N/A
  • Revenue
  • THAR N/A
  • TOVX N/A
  • Revenue This Year
  • THAR N/A
  • TOVX N/A
  • Revenue Next Year
  • THAR N/A
  • TOVX N/A
  • P/E Ratio
  • THAR N/A
  • TOVX N/A
  • Revenue Growth
  • THAR N/A
  • TOVX N/A
  • 52 Week Low
  • THAR $0.95
  • TOVX $0.37
  • 52 Week High
  • THAR $9.08
  • TOVX $4.97
  • Technical
  • Relative Strength Index (RSI)
  • THAR 50.85
  • TOVX 41.52
  • Support Level
  • THAR $4.94
  • TOVX $0.39
  • Resistance Level
  • THAR $7.25
  • TOVX $0.45
  • Average True Range (ATR)
  • THAR 1.50
  • TOVX 0.03
  • MACD
  • THAR -0.08
  • TOVX -0.00
  • Stochastic Oscillator
  • THAR 32.49
  • TOVX 15.80

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: